NCT03636503 2025-02-06Rituximab + Immunotherapy in Follicular LymphomaDana-Farber Cancer InstitutePhase 1 Terminated24 enrolled 25 charts
NCT03451825 2024-06-24Phase I/II Study of Avelumab in Pediatric Cancer ParticipantsEMD SeronoPhase 1 Terminated21 enrolled 21 charts